信息服务(III)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

III 信息服务

休市中 03-27 16:00:00 EDT

3.76

-0.11

-2.84%

盘后3.80

+0.04+1.06%

19:58 EDT

最高3.88	最低3.75	成交量19.85万
今开3.85	昨收3.87	日振幅3.23%
总市值1.80亿	流通市值1.29亿	总股本4,788万
成交额74.95万	换手率0.58%	流通股本3,423万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"III","market":"US","secType":"STK","nameCN":"信息服务","latestPrice":3.76,"timestamp":1774641600000,"preClose":3.87,"halted":0,"volume":198487,"hourTrading":{"tag":"盘后","latestPrice":3.8,"preClose":3.76,"latestTime":"19:58 EDT","volume":5713,"amount":21565.04,"timestamp":1774655896820,"change":0.04,"changeRate":0.010638,"amplitude":0.010638},"delay":0,"changeRate":-0.028423772609819202,"floatShares":34233044,"shares":47884104,"eps":0.190275,"marketStatus":"休市中","change":-0.11,"latestTime":"03-27 16:00:00 EDT","open":3.85,"high":3.875,"low":3.75,"amount":749461.4064205,"amplitude":0.0323,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.190275,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1774857600000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1171256400000,"exchange":"NASDAQ","adjPreClose":3.87,"dividendRate":0.047872,"preHourTrading":{"tag":"盘前","latestPrice":3.87,"preClose":3.87,"latestTime":"09:27 EDT","volume":15,"amount":58.1499975,"timestamp":1774618070139,"change":0,"changeRate":0,"amplitude":0.005168},"postHourTrading":{"tag":"盘后","latestPrice":3.8,"preClose":3.76,"latestTime":"19:58 EDT","volume":5713,"amount":21565.04,"timestamp":1774655896820,"change":0.04,"changeRate":0.010638,"amplitude":0.010638},"volumeRatio":0.7175895806262986,"impliedVol":1.7154,"impliedVolPercentile":0.8765},"requestUrl":"/m/hq/s/III","defaultTab":"news","newsList":[{"id":"2622830947","title":"益方生物(688382.SH)：D-2570治疗银屑病注册性III期临床试验完成全部受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2622830947","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622830947?lang=zh_cn&edition=full","pubTime":"2026-03-26 16:48","pubTimestamp":1774514885,"startTime":"0","endTime":"0","summary":"智通财经APP讯，益方生物(688382.SH)公告，公司自主研发的TYK2抑制剂D-2570用于治疗中重度斑块状银屑病(PsO)的注册性III期临床试验已于近日完成全部受试者入组。公告显示，D-2570是公司自主研发的一款靶向酪氨酸激酶2(TYK2)的新型口服选择性抑制剂，用于治疗银屑病等自身免疫性疾病。D-2570通过选择性结合TYK2假激酶域JH2部位，抑制TYK2激酶的活性，进而阻断TYK2依赖性的细胞因子信号传导介导的STAT蛋白的磷酸化，抑制炎症因子释放，参与免疫调节。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419477.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688382","III","BK4134"],"gpt_icon":0},{"id":"2622832953","title":"东方财富、同花顺、指南针、大智慧......互联网券商信息服务商业绩大扫描！有何亮点？","url":"https://stock-news.laohu8.com/highlight/detail?id=2622832953","media":"券商中国","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622832953?lang=zh_cn&edition=full","pubTime":"2026-03-26 12:18","pubTimestamp":1774498680,"startTime":"0","endTime":"0","summary":"互联网券商信息服务商业绩全部浮出水面。在去年上证指数创十年新高，A股成交额大增和投资者信心回暖之下，东方财富、同花顺、指南针、大智慧四家互联网券商信息服务商交出了各自在“AI+金融”浪潮中的年度答卷。业绩分化：东财领跑、指南针黑马从2025年四家互联网券商信息服务商业绩来看，可谓冰火两重天，分化明显。2025年指南针营收21.46亿元，同比增长40.39%；归属于上市公司股东净利润2.28亿元，同比激增118.74%，净利润实现翻倍增长，增速居首。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzA3NjM5MjIwOQ==&mid=2652259848&idx=2&sn=176691e7fb4c3e3b77efadf41dca1a84&chksm=85eae2a5d05f10699ea3525f9f71999e97e80ff953c5f98d40b3e0d00cad80e8386232e2af36&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["LU2097828631.EUR","III","LU1997244956.HKD","BK0028","BK0188","LU1064131003.USD","LU2097828557.USD","LU2580892862.HKD","BK0020","LU1981816686.USD","SG9999001093.SGD","LU0326950275.SGD","LU2097828474.EUR","LU2495084118.USD","BK0012","300803","BK0095","159792","BK0196","BK0272","LU1997245177.USD","BK0071","LU2097828805.USD","SG9999002950.SGD","LU2580892789.USD","LU1831875114.USD","BK0077","LU2148510915.USD","LU2097828714.EUR","160636","BK0102","601519","LU2289578879.USD","BK0201","BK0187","BK0055","LU1997245094.SGD","SG9999001069.SGD","300033","BK4134","BK0276","SG9999001051.SGD","300059","LU1064130708.USD","SG9999014674.SGD"],"gpt_icon":0},{"id":"2622881272","title":"港股异动 | 轩竹生物-B(02575)早盘涨超18% 吡洛西利III期BRIGHT-2临床研究结果于国际医学顶刊发表","url":"https://stock-news.laohu8.com/highlight/detail?id=2622881272","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622881272?lang=zh_cn&edition=full","pubTime":"2026-03-26 09:47","pubTimestamp":1774489669,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，轩竹生物-B早盘涨超18%，截至发稿，涨11.85%，报40.58港元，成交额1886.4万港元。消息面上，3月24日，轩竹生物-B发布公告，公司自主研发的新型CDK2/4/6抑制剂吡洛西利的III期BRIGHT-2临床研究最终分析结果，已于近日在国际顶尖医学期刊《美国医学会杂志·肿瘤学》正式在线全文发表。公司曾于2025年4月在《Nature Communications》期刊上公布BRIGHT-2研究的中期分析结果。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419250.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK0077","BK0096","BK0181","BK4585","BK4134","02575","000516","BK0042","BK0146","BK0188","BK1191","BK0046","BK0114","VXUS","BK0236","III"],"gpt_icon":0},{"id":"2622292100","title":"基石药业-B(02616)：舒格利单抗再获ESMO指南【I， A】推荐 ——用于III期非小细胞肺癌巩固治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2622292100","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622292100?lang=zh_cn&edition=full","pubTime":"2026-03-25 17:20","pubTimestamp":1774430400,"startTime":"0","endTime":"0","summary":"智通财经APP讯，基石药业-B 发布公告，公司核心商业化产品舒格利单抗获得欧洲肿瘤内科学会指南的级推荐。2025年2月，舒格利单抗联合化疗已获得ESMO《非驱动基因阳性转移性非小细胞肺癌动态临床指南》的推荐，用于鳞状及非鳞状IV期非小细胞肺癌双适应症的一线治疗。至此，舒格利单抗在欧盟及英国获批的两项肺癌适应症均已被纳入ESMO指南，充分体现了其临床价值。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418760.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1574","02616","III","BK4134"],"gpt_icon":0},{"id":"2622041766","title":"宝济药业-B(02659)：KJ103用于肾移植脱敏治疗III期临床试验随访完成","url":"https://stock-news.laohu8.com/highlight/detail?id=2622041766","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622041766?lang=zh_cn&edition=full","pubTime":"2026-03-25 13:22","pubTimestamp":1774416121,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宝济药业-B 发布公告，KJ103作为脱敏疗法用于中国等待肾脏移植的高敏感患者的III期临床试验，已于2026年3月20日完成所有入组受试者的主要试验随访。于2025年8月，公司启动了KJ103用于高度致敏肾移植患者脱敏治疗的III期临床试验，旨在有效清除预存的HLA抗体并预防超急性排斥反应。于2024年11月，公司就KJ103的该适应症获得了国家药监局对KJ103的突破性治疗药物认定。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418590.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02659","BK1161","BK4134","III"],"gpt_icon":0},{"id":"2621206968","title":"轩竹生物-B(02575)：吡洛西利联合氟维司群治疗HR+/HER2-晚期乳腺癌III期临床研究最终分析结果于国际顶尖期刊《JAMA Oncology》发表","url":"https://stock-news.laohu8.com/highlight/detail?id=2621206968","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621206968?lang=zh_cn&edition=full","pubTime":"2026-03-24 19:12","pubTimestamp":1774350738,"startTime":"0","endTime":"0","summary":"智通财经APP讯，轩竹生物-B 发布公告，公司自主研发的新型CDK2/4/6抑制剂吡洛西利的III期BRIGHT-2临床研究最终分析结果，已于近日在国际顶尖医学期刊《美国医学会杂志·肿瘤学》正式在线全文发表。BRIGHT-2研究最终分析结果显示，吡洛西利联合氟维司群为患者带来了具有临床意义且持久稳健的获益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418161.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02575","HR","BK4134","BK4203","BK4225","III","BK1191"],"gpt_icon":0},{"id":"2621406605","title":"远大医药(00512)核药战略伙伴Telix全球首创rADC国际多中心III期获积极进展，前列腺癌治疗添新希望！","url":"https://stock-news.laohu8.com/highlight/detail?id=2621406605","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621406605?lang=zh_cn&edition=full","pubTime":"2026-03-24 18:59","pubTimestamp":1774349976,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，近日，远大医药核药领域战略合作伙伴澳洲Telix公司传来重磅利好，其用于治疗前列腺癌的全球首创的镥标记的治疗性放射性抗体药物偶联物候选药物TLX591-Tx国际多中心III期临床试验的第一部分已成功达到主要目标，证明了该产品的安全性和耐受性，且未观察到新的不良反应，不仅促进了该创新产品未来的进一步开发及上市，同时也体现了前列腺癌治疗未来有望获得全新选择。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418146.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["000876","BK0028","BK0012","BK0196","III","BK0187","BK0183","BK1191","BK4134","BK0188","00512","BK0238"],"gpt_icon":0},{"id":"2621603174","title":"轩竹生物-B(02575)涨逾8% 安久卫治疗反流性食管炎III期试验完成全部受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2621603174","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621603174?lang=zh_cn&edition=full","pubTime":"2026-03-24 10:10","pubTimestamp":1774318245,"startTime":"0","endTime":"0","summary":"消息面上，四环医药发布公告，公司旗下非全资附属公司轩竹生物科技股份有限公司的创新药安奈拉唑钠肠溶片用于治疗成人反流性食管炎的中国III期临床试验已顺利完成全部500名受试者入组。据悉，安奈拉唑钠肠溶片于2023年6月获得中国国家药品监督管理局批准上市，用于患者治疗十二指肠溃疡。此次III期临床研究于2025年7月全面展开，近期完成受试者入组，标志着本公司在创新药物研发方面取得了重要进展。","market":"sg","thumbnail":"https://static.szfiu.com/news/20241108/YjNiOTNjODIxNjM4MTUzMTI5MQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YjNiOTNjODIxNjM4MTUzMTI5MQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977089","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1593","BK1600","00460","BK1515","III","02575","BK1191","BK4134"],"gpt_icon":0},{"id":"2621337490","title":"康宁杰瑞制药-B(09966)：KN026辅助治疗HER2+乳腺癌III期临床研究完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2621337490","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621337490?lang=zh_cn&edition=full","pubTime":"2026-03-24 08:07","pubTimestamp":1774310843,"startTime":"0","endTime":"0","summary":"双靶向联合化疗辅助治疗HER2+ BC 对比仅含曲妥珠单抗的方案，可进一步降低复发风险，其中淋巴结阳性人群的获益最为显著。KN026-007是一项随机、对照、开放、多中心III期临床研究，预计纳入约1,800例术后组织学确认区域淋巴结阳性数量≥4个的可切除HER2+ BC患者。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417758.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["III","BK1574","09966","BK4134","BK1161"],"gpt_icon":0},{"id":"2621672560","title":"华莱士成立信息服务公司，注册资本5000万","url":"https://stock-news.laohu8.com/highlight/detail?id=2621672560","media":"经济观察网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621672560?lang=zh_cn&edition=full","pubTime":"2026-03-23 10:40","pubTimestamp":1774233600,"startTime":"0","endTime":"0","summary":"经济观察网 天眼查工商信息显示，近日，福州华莱士信息有限公司成立，法定代表人为华鹏程，注册资本5000万人民币，经营范围为社会经济咨询服务、企业管理咨询、企业管理、供应链管理服务。股东信息显示，该公司由福建省华莱士食品股份有限公司全资持股。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2026-03-23/doc-inhrxvtz4211545.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-03-23/doc-inhrxvtz4211545.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["III","BK4134"],"gpt_icon":0},{"id":"2621747577","title":"和黄医药(00013)启动HMPL-760用于治疗复发/难治性弥漫性大B细胞淋巴瘤的中国III期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2621747577","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621747577?lang=zh_cn&edition=full","pubTime":"2026-03-23 08:08","pubTimestamp":1774224537,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和黄医药 发布公告，本公司今日宣布在中国启动HMPL-760联合R-GemOx 方案用于治疗复发/难治性弥漫性大 B细胞淋巴瘤患者的注册性III期临床试验。该研究是一项随机、双盲、阳性对照的III期临床研究，旨在评估HMPL-760联合R-GemOx方案对比安慰剂联合RGemOx方案用于治疗既往接受过一线系统化疗、免疫治疗或免疫化疗联合治疗后复发或难治性且不适合移植的弥漫性大B细胞淋巴瘤患者的疗效、安全性和药代动力学。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417131.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK1587","HCM","BK4134","III","BK4585","BK1191","BK1588","BK4531","00013","BK4007"],"gpt_icon":0},{"id":"2621742594","title":"宜明昂科-B(01541)成功完成IMM01(替达派西普)用于慢性粒-单核细胞白血病(CMML)一线治疗的III期临床试验中期分析的133例患者招募","url":"https://stock-news.laohu8.com/highlight/detail?id=2621742594","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621742594?lang=zh_cn&edition=full","pubTime":"2026-03-23 07:22","pubTimestamp":1774221759,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宜明昂科-B 发布公告，本公司成功完成IMM01用于慢性粒-单核细胞白血病一线治疗的III期临床试验中期分析的133例患者招募。此外，IMM01的CD47结合结构域经过特别改造能够避免与人体红细胞结合。凭藉差异化的分子设计，IMM01表现出良好的安全性并证实其激活巨噬细胞的能力。IMM01联合阿扎胞苷进行CMML一线治疗于2023年11月获美国食品药品监督管理局授予的孤儿药资格认定。本集团拥有IMM01的全球知识产权及商业化权利。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417114.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","01541","III","BK4134"],"gpt_icon":0},{"id":"2621124714","title":"四环医药附属创新药III期临床试验完成500名受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2621124714","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621124714?lang=zh_cn&edition=full","pubTime":"2026-03-22 18:34","pubTimestamp":1774175640,"startTime":"0","endTime":"0","summary":"3月22日，四环医药（00460）发布公告，本公司旗下非全资附属公司轩竹生物科技股份有限公司的创新药安奈拉唑钠肠溶片（商品名：安久卫?）用于治疗成人反流性食管炎的中国III期临床试验已顺利完成全部500名受试者入组。该试验是一项多中心、随机、双盲双模拟、阳性药物平行对照的关键性研究，旨在评估安奈拉唑钠肠溶片治疗中国成年反流性食管炎受试者的有效性和安全性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603223679754978.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06978","BK4134","BK1593","III","BK1515","159992","00460","BK1161","BK1191","BK1574","BK1600"],"gpt_icon":0},{"id":"2621714992","title":"轩竹生物-B(02575)：安奈拉唑钠肠溶片(安久卫®)治疗反流性食管炎中国III期临床试验完成全部受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2621714992","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621714992?lang=zh_cn&edition=full","pubTime":"2026-03-22 18:33","pubTimestamp":1774175605,"startTime":"0","endTime":"0","summary":"智通财经APP讯，轩竹生物-B 发布公告，公司自主研发的创新药安奈拉唑钠肠溶片用于治疗成人反流性食管炎的中国III期临床试验已于近日顺利完成全部500名受试者入组。该项III期临床试验是一项多中心、随机、双盲双模拟、阳性药物平行对照的关键性研究，旨在评估安奈拉唑钠肠溶片治疗中国成年反流性食管炎受试者的有效性和安全性。安全性指标主要为不良事件的发生类型、发生率、严重程度。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417067.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","02575","BK4134","III"],"gpt_icon":0},{"id":"2621719302","title":"迪哲医药(688192.SH)：舒沃哲®单药一线治疗EGFRexon20ins非小细胞肺癌国际多中心III期临床试验获阳性顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2621719302","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621719302?lang=zh_cn&edition=full","pubTime":"2026-03-22 15:43","pubTimestamp":1774165425,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迪哲医药(688192.SH)公告，公司自主研发的产品舒沃哲®(ZEGFROVY®，通用名：舒沃替尼片)单药一线治疗表皮生长因子受体(EGFR)20号外显子插入突变(exon20ins)晚期非小细胞肺癌(NSCLC)的国际多中心III期临床研究“悟空28”(WU-KONG28)达到主要研究终点、取得阳性顶线结果，是全球首个且唯一在国际多中心随机对照III期临床研究中，针对EGFRexon20ins NSCLC一线治疗取得阳性结果的口服靶向药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417047.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688192","BK0239","III","BK4134"],"gpt_icon":0},{"id":"2620270254","title":"康宁杰瑞制药-B(09966.HK)：JSKN016用于治疗TNBC的III期临床研究完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2620270254","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620270254?lang=zh_cn&edition=full","pubTime":"2026-03-20 08:17","pubTimestamp":1773965823,"startTime":"0","endTime":"0","summary":"格隆汇3月20日丨康宁杰瑞制药-B发布公告，JSKN016用于治疗三阴性乳腺癌的一项III期临床研究已成功完成首例患者给药。TNBC约占所有BC病例的15%至20%。　　JSKN016-301是一项开放、随机、对照、多中心III期临床研究，预计将在中国约60家临床研究中心开展。该研究计划入组经至少二线系统性治疗失败的不可手术切除的局部晚期、复发或转移性TNBC患者。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260320/32083524.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK4134","BK1574","III","BK1161","09966"],"gpt_icon":0},{"id":"2620225813","title":"吉利德科学(GILD.US)CD19/CD20 CAR-T细胞疗法启动III期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2620225813","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620225813?lang=zh_cn&edition=full","pubTime":"2026-03-19 21:12","pubTimestamp":1773925932,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，3月18日，美国临床试验收录网站显示，吉利德科学旗下公司Kite Pharma启动了KITE-753的首个III期临床试验。KITE-753是一款靶向CD19和CD20的双顺反子自体CAR-T细胞疗法。研究的主要终点是第6个月实现完全缓解的患者比例和36个月内的无事件生存期。结果显示，剂量3队列，在14例未接受过CAR-T细胞疗法治疗的患者中，11例实现CR，CR率为79%;总人群，在20例未接受过CAR-T细胞疗法治疗的患者中，14例实现CR，CR率为70%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1416170.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SG9999015978.USD","LU0965508806.USD","LU0823416689.USD","LU1037948541.HKD","GILD","IE00B19Z3581.USD","LU1571399168.USD","LU1066051498.USD","LU1674673428.USD","LU0965509101.SGD","LU0965509283.SGD","LU0965509010.AUD","LU1061106388.HKD","LU2087621335.USD","SG9999015945.SGD","BK4022","LU0114720955.EUR","BK4134","LU1839511570.USD","IE00B3T34201.USD","SG9999015986.USD","LU1934455863.HKD","LU1674673691.USD","LU2112291526.USD","IE0002270589.USD","LU0861579265.USD","SG9999015952.SGD","LU0234570918.USD","BK4588","CAR","BK4568","IE00BZ1G4Q59.USD","LU0058720904.USD","BK4139","LU0882574055.USD","BK4583","IE00B19Z3B42.SGD","LU0109394709.USD","IE00BKVL7J92.USD","LU1037948897.HKD","III","LU1066053197.SGD","BK4532","LU0122379950.USD","LU1585245621.USD","LU1430594728.SGD","LU1023059063.AUD","LU2089984988.USD","LU0289739699.SGD","LU0889565916.HKD"],"gpt_icon":0},{"id":"2620256274","title":"开拓药业-B(09939)：KX-826酊1.0%治疗中国成年男性雄激素脱发关键性临床试验III期阶段达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2620256274","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620256274?lang=zh_cn&edition=full","pubTime":"2026-03-18 20:59","pubTimestamp":1773838785,"startTime":"0","endTime":"0","summary":"智通财经APP讯，开拓药业-B 发布公告，其自主研发、潜在同类首创的 KX-826酊1.0%治疗脱发的关键性临床试验III期阶段已获得顶线数据。KX-826作为公司目前进展最快的外用创新药物之一，自开发以来已在中国和美国完成针对男性及女性的多项用于治疗脱发的临床试验，并表现出优异的有效性及安全性。该药物和KX-826均有望作为一种治疗雄激素性脱发的全新疗法，为广大脱发患者提供了更安全且有效的治疗选择。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1415598.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4134","BK1574","III","BK1515","BK1161","09939"],"gpt_icon":1},{"id":"2618985985","title":"港股异动 | 和誉-B(02256)再涨超9% 贝捷迈全球III期MANEUVER研究结果荣登《柳叶刀》","url":"https://stock-news.laohu8.com/highlight/detail?id=2618985985","media":"智通财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618985985?lang=zh_cn&edition=full","pubTime":"2026-03-10 13:36","pubTimestamp":1773121010,"startTime":"0","endTime":"0","summary":"和誉-B(02256)再涨超9%，截至发稿，涨8.76%，报12.91港元，成交额2199.69万港元。","market":"fut","thumbnail":"https://img.zhitongcaijing.com/image/20260310/20260310133720_71529.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260310/20260310133720_71529.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1412041.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU2778985437.USD","BK4588","VXUS","IE00BPRC5H50.USD","LU2476274308.USD","LU2488822045.USD","BK4585","IE00B543WZ88.USD","III","02256","BK1161","LU2476274720.SGD","BK4134","IE00B5MMRT66.SGD"],"gpt_icon":0},{"id":"2618692617","title":"和誉-B(02256)：《柳叶刀》(The Lancet)发布贝捷迈®全球III期MANEUVER研究结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2618692617","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618692617?lang=zh_cn&edition=full","pubTime":"2026-03-09 08:03","pubTimestamp":1773014618,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和誉-B(02256)发布公告，公司的附属公司上海和誉生物医药科技有限公司(和誉医药)宣布，其自主研发的新型、口服、高选择性且高效的小分子CSF-1R抑制剂贝捷迈®(盐酸匹米替尼胶囊，ABSK021)的全球多中心III期MANEUVER研究结果，于3月5日(西欧时间)正式发表于国际医学期刊《柳叶刀》 (The Lancet)1。此次发表标志着和誉医药这一创新疗法在临床研究质量、数据完整性及国际学术认可度方面取得了重要里程碑。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1411363.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00B5MMRT66.SGD","III","BK4134","LU2778985437.USD","IE00B543WZ88.USD","LU2476274308.USD","02256","IE00BPRC5H50.USD","BK1161","LU2476274720.SGD","LU2488822045.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.isg-one.com","stockEarnings":[{"period":"1week","weight":-0.0157},{"period":"1month","weight":-0.1983},{"period":"3month","weight":-0.3649},{"period":"6month","weight":-0.3702},{"period":"1year","weight":-0.0027},{"period":"ytd","weight":-0.3495}],"compareEarnings":[{"period":"1week","weight":-0.0223},{"period":"1month","weight":-0.0852},{"period":"3month","weight":-0.0814},{"period":"6month","weight":-0.0419},{"period":"1year","weight":0.1182},{"period":"ytd","weight":-0.0701}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Information Services Group, Inc.于2006年7月20日在特拉华州注册成立。该公司是一家全球领先的技术研究和咨询公司。ISG是超过900家客户、超过75家百强企业值得信赖的商业伙伴，致力于帮助企业、公共部门组织以及服务和技术提供商实现卓越运营和更快增长。该公司专门从事数字化转型服务，包括自动化、云和数据分析；采购咨询；托管治理和风险服务；网络载体服务；技术战略和运营设计；变革管理；市场情报和技术研究与分析。","yearOnYearQuotes":[{"month":1,"riseRate":0.444444,"avgChangeRate":0.022101},{"month":2,"riseRate":0.5,"avgChangeRate":0.004642},{"month":3,"riseRate":0.315789,"avgChangeRate":0.029588},{"month":4,"riseRate":0.444444,"avgChangeRate":-0.008159},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.028576},{"month":6,"riseRate":0.5,"avgChangeRate":0.015439},{"month":7,"riseRate":0.444444,"avgChangeRate":0.01427},{"month":8,"riseRate":0.555556,"avgChangeRate":0.010481},{"month":9,"riseRate":0.444444,"avgChangeRate":-0.004212},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.036611},{"month":11,"riseRate":0.611111,"avgChangeRate":0.053419},{"month":12,"riseRate":0.555556,"avgChangeRate":0.003262}],"exchange":"NASDAQ","name":"信息服务","nameEN":"Information"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"信息服务(III)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供信息服务(III)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"信息服务,III,信息服务股票,信息服务股票老虎,信息服务股票老虎国际,信息服务行情,信息服务股票行情,信息服务股价,信息服务股市,信息服务股票价格,信息服务股票交易,信息服务股票购买,信息服务股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"信息服务(III)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供信息服务(III)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}